Table 3.
Results from TANGO II Comparing Meropenem 2 g/Vaborbactam 2 g Infused Over 3 Hr Q8h or Adjusted Dose versus Best Available Therapy for the Treatment of Confirmed CRE Infections in the mCRE-MITT Population in Patients Treated for cUTI or AP45,46
| Type of Outcome | Meropenem/Vaborbactam | Best Available Therapy | Absolute Difference | Relative Difference |
|---|---|---|---|---|
| Overall success at EOT | 75.0% (9/12) | 50.0% (2/4) | 25.0 | 50 |
| Overall success at TOC | 33.3% (4/12) | 50.0% (2/4) | −16.7 | −33.4 |
| Clinical cure at EOT | 72.7% (8/11) | 50.0% (2/4) | ||
| Clinical cure at TOC | 57.1% (4/7) | 50.0% (2/4) | ||
| Microbial cure at EOT | 72.7% (8/11) | 50.0% (2/4) | ||
| Microbial cure at TOC | 50.0% (4/8) | 50.0% (2/4) |
Abbreviations: EOT, end of treatment; TOC, test of cure.